- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about MRK
Recent news which mentions MRK
10 Health Care Stocks With Whale Alerts In Today's Session
November 13, 2024
From Benzinga
3 Stocks Poised for a Breakout
November 09, 2024
From Motley Fool
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
November 08, 2024
From Benzinga
2 Hot Biopharma Stocks to Buy and Hold for 5 Years
November 08, 2024
From Motley Fool
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.
November 07, 2024
From Motley Fool
Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
November 07, 2024
From Benzinga
Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom
November 06, 2024
From Benzinga
2 Magnificent Stocks to Buy That Are Near 52-Week Lows
November 05, 2024
From Motley Fool
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
November 04, 2024
From Benzinga
Is Pfizer Stock a Bargain for Long-Term Investors?
November 04, 2024
From Motley Fool
Is It Time to Buy October's Worst-Performing Dow Jones Stocks?
November 03, 2024
From Motley Fool
3 Magnificent Stocks Under $100 to Buy in November
November 03, 2024
From Motley Fool
2 Dividend Stocks to Buy for a Lifetime of Passive Income
November 02, 2024
From Motley Fool
Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease
November 01, 2024
From Benzinga
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
October 31, 2024
From Benzinga
Merck Beats Q3 Estimates, But Lowers Annual Forecast As Gardasil Vaccine Hit By Low China Demand
October 31, 2024
From Benzinga
3 Dividend Stocks That Could Raise Their Payouts in November
October 31, 2024
From Motley Fool
A Look Into Merck & Co Inc's Price Over Earnings
October 29, 2024
From Benzinga
Why Is Moderna Stock Trading Higher On Monday?
October 28, 2024
From Benzinga
Pfizer, Live Nation Entertainment And More On CNBC's 'Final Trades'
October 25, 2024
From Benzinga
CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines
October 24, 2024
From Benzinga
3 Absurdly Cheap Stocks That Pay High Dividends
October 24, 2024
From Motley Fool
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio
October 23, 2024
From Benzinga
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
October 21, 2024
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.